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Th e carnitine shuttle, consisting of the enzymes carnitine palmitoyltransferase 
(CPT) 1 and 2 and carnitine-acylcarnitine translocase (CACT), is of importance 
for the regulation of fatty acid oxidation and whole body energy supply. In humans, 
CPT1a-defi ciency is associated with hypoketotic and hyperglycemic events. To de-
velop new therapeutic options for this defi ciency, mice defi cient in CPT1a have been 
generated. In this study we used male mice heterozygous (HE) for CPT1a -defi ciency. 
Th ese mice were fed a high fat (HF) diet to test the hypothesis that mildly impaired 
β-oxidation enhances the susceptibility to develop impaired glucose metabolism 
upon HF feeding. CPT1a+/-mice fed a HF diet showed only subtle changes in fat and 
glucose metabolism as was evident from assessment of several hepatic and plasma 
parameters as well as whole body glucose kinetics and hepatic gene expression levels. 
Th us, this study refutes our hypothesis since HF feeding in HE mice resulted in plas-
ma glucose and insulin concentrations very similar to those observed in wild-type 
control mice. Th e phenotype in HE mice appeared to be much more complex than 
reported so far, with only subtle changes in hepatic lipid and glucose metabolism.
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introDUction
Fat storage in the liver depends on the net balance of fatty acid uptake, mitochondrial 
fatty acid oxidation (FAO), de novo lipogenesis and triglyceride (TG) secretion in the 
form of VLDL particles. In addition, biliary phospholipid secretion contributes to 
hepatic fatty acid turnover. FAO starts with the transport of the acyl-residue in acyl-
CoA from the cytosol into the mitochondrial matrix [1,2]. Th is is accomplished by 
the so-called carnitine shuttle. Carnitine palmitoyltransferase 1 (CPT1) is the fi rst 
enzyme of the carnitine shuttle which further consists of carnitine-acylcarnitine 
translocase (CACT) and carnitine palmitoyltransferase 2 (CPT2) [1,2]. CPT1 cata-
lyzes the condensation of the fatty acid acyl-residue from acyl-CoA with carnitine 
leading to the formation of acylcarnitine, which can subsequently be transported 
across the mitochondrial membrane by CACT in exchange of carnitine. Th is is 
followed by the action of CPT2 which, inside the mitochondria, transfers the acyl-
residue back into CoA to regenerate acyl-CoA. Th is acyl-CoA is then available to be 
oxidized by intra-mitochondrial β-oxidation enzymes to fi nally yield acetyl-CoA. 
Th e activity of CPT1 is allosterically inhibited by malonyl-CoA. Malonyl-CoA is 
generated from the carboxylation of two acetyl-CoA moieties by one of the acetyl-
CoA carboxylase (ACC) isoforms. ACC1 generates malonyl-CoA which is primarily 
used in de novo lipogenesis, whereas ACC2 generates malonyl-CoA that inhibits 
CPT1 and therefore FAO [3,4]. In this way, the activities of fatty acid oxidation and 
synthesis are physiologically balanced to optimally meet the demands of the body.
In humans, CPT1a defi ciency presents with hypoketotic hypoglycemia due to 
the lack of fatty acid transport though the mitochondria leading to impaired FAO, 
ketogenesis and acetyl-CoA for ATP-production [5,6]. Attempts have been made to 
generate a knockout mice model for CPT1a to evaluate the etiology of the presenting 
symptoms in an animal model and to design therapeutic options. However, lack-
ing this gene appeared to be embryonically lethal in mice [7]. Quite surprisingly, 
mice heterozygous for CPT1a-defi ciency appeared to display a metabolic phenotype, 
although rather mild. Glucose concentration in plasma was mildly but signifi cantly 
decreased aft er 24 h of fasting in CPT1a+/- mice while plasma free fatty acid concen-
tration was somewhat increased [7]. Similar observations have not been reported in 
human obligate heterozygotes of CPT1a mutations [5,6].
Experiments in which overexpression of CPT1a was achieved by transduction 
with an adenoviral construct showed an enhanced expression of CPT1a in liver 
resulting in reduced hepatic triglyceride levels [8] and enhanced ketogenesis [8–10]. 
Results obtained in L6E9 muscle cells in which CPT1 was overexpressed showed that 
these cells were protected from fatty acid-induced insulin resistance [9–11]. Appar-
ently, enhanced expression of CPT1 by itself stimulates mitochondrial β-oxidation 
and ketogenesis and therefore prevents diet-induced insulin resistance.
In the current experiments, mice heterozygous (HE) for Cpt1a -defi ciency were fed 




the susceptibility to develop impaired glucose metabolism upon HF feeding. We 
used HE mice on a mixed C57Bl/6-Sv129 background, since it is known that feeding 
mice of this strain a HF diet induces insulin resistance and glucose intolerance [12]. 
Aft er 4 weeks on a HF diet, whole body glucose kinetics was studied aft er injecting a 
bolus of [6, 6-2H2]-glucose intraperitonally and the decay of isotope enrichment in 
time was measured. Th e results of this study refuted our hypothesis since HF feeding 
in HE mice resulted in glucose and insulin concentrations in plasma very similar 
to those observed in wild-type (WT) control mice. Th e phenotype appeared to be 
much more complex than reported until now with only subtle changes in hepatic 
lipid and glucose metabolism in HE mice.
MateriaL anD MethoDs
Animals and experimental design
Male and female Cpt1a+/- and their wild-type (WT) littermates on a mixed C57Bl/6-
Sv129 background were kindly provided by Dr. P.A. Wood (Birmingham, Alabama, 
USA) [7] and bred and housed in an environmentally-controlled facility. Mice were 
genotyped by multiplex PCR using the following primers: CPT1aF: cacgagc-
cagactcctcagcagcaggt; CPT1aR: gtaggaaacaccatagccgtcatcagc; NeoF: 
gatggattgcacgcaggttc; NeoR: taaagcacgaggaagcggtcag
HE mice showed two bands (CPT1a band of 326 bp and a neomycine band of 
700 bp) whereas WT mice showed only the CPT1a band of 326 bp. A representative 
picture for HE and WT mice is shown in fi gure 1. Mice had free access to food and 
water. All experiments were performed in male mice and were in accordance with 
local guidelines for the use of experimental animals. Mice (12 weeks of age) of each 
genotype were randomized into two groups. Th ey were fed either a normal lab chow 
diet (52 energy% of carbohydrates, 35 energy% of protein and 13 energy% of fat 
(Abdiets, Woerden, Th e Netherlands)), or a high fat (HF) diet (21 energy% of carbo-
hydrate 21 energy% of protein and 58 energy% of fat as lard (Abdiets, Woerden, Th e 
Netherlands)) for 4 weeks.
Basal experiment
For the measurements of basal liver and plasma parameters, mice were sacrifi ced 
aft er 4 h or 15 h of fasting by cardiac puncture under isofl urane anesthesia. Livers 
were removed quickly, immediately snap-frozen in liquid nitrogen and stored at -80 
°C until analysis. Blood samples were immediately centrifuged at 5000 rpm for 5 
min. Plasma was collected and stored at -20°C for later analysis.
Biochemical analyses
Liver lipid extraction was performed according to the procedure of Bligh and Dyer 
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[13]. Protein concentrations of these livers were determined according to the method 
of Lowry [14]. Hepatic concentrations of triglycerides (TG), free and total cholesterol 
were determined using commercially available kits (Roche Diagnostics, Mannheim, 
Germany and Wako Chemicals, Neuss, Germany). Hepatic glycogen levels were 
measured as described by Keppler et al. [15]. Malonyl-CoA content of the liver was 
measured according to the protocol of Demoz et al. [16] with minor modifi cations 
on a Nova-Pak C-18 column (Waters, Etten Leur, Th e Netherlands) [17].
CPT1 activity was assessed using a modifi ed version of an assay developed for hu-
man fi broblasts [18]. In short, liver tissue was homogenized in PBS (0.15-0.25% w/v). 
Th e resulting homogenate was diluted 5 times in PBS followed by sonication (twice 
at 8-watt output, 40 J, on ice). Th e homogenates were centrifuged for 5 minutes at 
1000g. Protein concentration was determined in the supernatant. CPT1 activity was 
determined in duplicate using the forward reaction by measuring the formation 
of [U-13C]-palmitoylcarnitine from carnitine and [U-13C]-palmitoyl-CoA. CPT1 
activity is defi ned as the activity in nmol/min/mg protein inhibited by 200mM 
malonyl-CoA. Th erefore all samples are measured in the presence and absence of 
malonyl-CoA. Each assay was performed in a 250mL reaction mixture containing 
150mM KCl, 25mM Tris, 2mM EDTA, 20mM KH2PO4, 4.5mM reduced glutathi-
one, 0.5mM L-carnitine, 1mg/mL BSA (15mM) and 25mM [U-13C]-palmitoyl-CoA 
(pH7.0, palmitoyl-CoA/BSA ratio is 1.67). Th e reaction mixture contained approxi-
mately 5mg of liver protein extract. Samples were incubated for 10 minutes at 37°C 
aft er which the reaction was terminated by the addition of 800mL acetonitril con-
taining [2H3]-propionylcarnitine, [2H3]-octanoylcarnitine and [2H3]-palmitoyl-
carnitine. Quantifi cation of the formed [U-13C]-palmitoylcarnitine was performed 
using tandem mass spectrometry as described by Van Vlies et al. [18].
Plasma analyses
Plasma TG, free and total cholesterol and free fatty acids of 4 h and 15 h fasted mice 
were determined using commercially available kits (Roche Diagnostics, Mannheim, 
Germany and Wako Chemicals, Neuss, Germany). Total ketone bodies of 4 h and 15 
h fasted mice were determined with the total ketone bodies kit using 4 µl of plasma 
(Wako Chemicals, Neuss, Germany). Total carnitine and acyl-carnitines from blood 
spots of fed and 15 h fasted mice were measured with tandem mass spectrometry 
according to Chace et al. [19] with minor modifi cations [17].
RNA isolation and mRNA levels by Real Time PCR
RNA was isolated from livers of 4 h fasted mice with Tri-reagents according to 
manufacturer guidelines (Sigma, Zwijndrecht, Th e Netherlands). Th e concentra-
tion of RNA was determined in 1 μl of RNA solution using the Nanodrop system 
(ND1000, Isogen Life Science, IJsselstein, Th e Netherlands). Th e cDNA reaction was 




Zwijndrecht, Th e Netherlands). Quantitative real time PCR was performed using 
qPCR core kit (Eurogentech, Seraing, Belgium). PCR results were normalized to 
36B4 mRNA levels.
Glucose kinetics
At the start and at the end of the dietary period mice glucose kinetics was measured in 
over-night fasted mice. Mice received an i.p. injection of a bolus of [6,6-2H2]-glucose 
(110 mmol/l; 5ml/kg BW). Sequential blood spots were taken by tail bleeding every 
10 min for 90 min for GC-MS analyses of isotopic enrichments in blood glucose. 
Blood glucose levels were measured every 10 minutes with a Lifescan glucose meter 
(Lifescan Benelux, Beerse, Belgium). Analytical procedures for extraction of isotopi-
cally labelled glucose from blood spots, derivatization of the extracted glucose into 
penta-acetate glucose derivative and GC-MS measurements of this derivative were 
performed according to Van Dijk et al. [20,21]. Th e fractional isotopomer distribu-
tion measured by GC-MS (m0-m2) was corrected for the fractional distribution due 
to natural abundance by multiple linear regression as described by Katz et al. [22] to 
obtain the excess fractional distribution of mass isotopomers (M0-M2) due to dilu-
tion of [6,6-2H2]-glucose. Th e excess fractional distribution of mass isotopomers 
was fi tted to a single compartmental model of glucose kinetics for the calculation of 
glucose production and consumption using SAAM-II soft ware (version 1.2.1, SAAM 
Institute, University of Washington, Seattle, WA, USA). Plasma insulin levels aft er 
the whole body glucose test were determined using the insulin ultra sensitive mouse 
ELISA kit (Mercodia, Upsala, Sweden).
Statistics
All values represent mean ± standard deviation for the number of animals indicated. 
Statistical analysis was assessed by Kruskall-Wallis and Mann-Whitney U tests cor-
rected for multiple groups. Th e level of signifi cance was set at p<0.05. Th e soft ware 
used for the analysis was SPSS 12.01 for Windows (SpSS, Chigaco, IL, USA).
resULts
CPT1a+/- did not show decreased total CPT1 activity in liver
Mice were divided into WT and HE groups based on genotyping by multiplex PCR 
(Figure 1). Total CPT1 activities measured in liver tissue are shown for WT and HE 
mice on chow or HF feeding for 4 weeks (Figure 2). Quite strikingly, no diﬀ erence 
in liver CPT1 activity was observed between WT and HE mice when fed lab chow 
(Figure 2). HF feeding for 4 weeks in HE mice had a counterintuitive eﬀ ect on CPT1 
activity, i.e., HF increased CPT1 activity to values almost twice as high when com-
pared to WT on a HF diet (Figure 2). Furthermore, CPT1 activity in HE mice on HF 
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diet was increased signifi cantly compared to that observed in HE mice on lab chow. 
Th is striking eﬀ ect of HF feeding was not observed in WT mice.
CPT1a+/- did not show altered glucose and lipid parameters in plasma and liver 
upon fasting
WT and HE mice were fed a HF-diet for 4 weeks and at the end of the dietary period 
fasted for diﬀ erent lengths of time (Table 1). When mice on a chow diet were fasted 
for 15 h, HE mice showed a tendency towards elevated plasma TG levels compared 
to WT mice, however, these diﬀ erences did not reach statistical signifi cance. Th e 
eﬀ ects of HF feeding on plasma parameters were similar in both genotypes aft er 4 
h and 15 h of fasting. Fasting of HE mice for 4 h or 15 h did not modulate ketone 
body concentrations in plasma diﬀ erent from those in WT mice. WT mice fed a 
HF diet followed by 15 h of fasting showed a signifi cant drop in β-hydroxybutyrate 
(BHB) levels compared to chow-fed WT mice. In the liver, subtle diﬀ erences in TG 
content were observed during fasting between WT and HE mice. In chow-fed WT 
and HE mice 4 h of fasting resulted in very similar changes in hepatic TG contents. 
In contrast, when chow-fed WT and HE mice were fasted for 15 h an increase in he-
patic TG content was observed that was more pronounced in HE mice. Th ere was no 
additional eﬀ ect on hepatic TG levels in either genotype upon fasting on HF feeding.
Aft er 15 h of fasting hepatic malonyl-CoA content tended to be decreased in HF-
fed animals when compared to chow fed animals, however, this diﬀ erence did not 
reach statistical signifi cance. No eﬀ ects of genotype on malonyl-CoA levels were 
observed.
Figure 2: CPT1 activity in livers of WT and HE mice fed a chow or HF diet. * p<0.05 vs chow. 
Figure 1: Representative picture of multiplex PCR for genotyping of CPT1a+/- mice. WT mice show only 




CPT1a+/- mice show differences in fasting-associated alterations of hepatic acylcar-
nitine content only during HF feeding.
Table 2 shows the eﬀ ect of CPT1a heterozygosity on the contents of free and total 
carnitine and the molar ratio of free carnitine (C0) over the sum of palmitoyl- 
(C16:0) and stearylcarnitine (C18:0). Th is ratio is considered to be indicative for 
CPT1 defi ciency in humans [6]. In WT mice on chow, 15 h of fasting resulted in 
acylation of carnitine: the content of free carnitine decreased together with the mo-
lar ratio of C(0)/(C16:0+C18:0). In HE mice on chow the same eﬀ ect was observed 
and to a similar extent. In HF-fed WT mice, however, free carnitine concentrations 
Table 1: Plasma and liver basal parameters of WT and HE mice fed a chow or high fat diet a er 4 h and 
15 h of fasting. Values represent mean ± stdev. a: p<0.05 versus WT chow, b: p<0.05 versus HE chow, c: p<0.05 
versus WT HF, *: p<0.05 versus 4 hr fast
4 h fast (n=5-6 animals per group) 15 h fast (n=4 animals per group)
Chow HF Chow HF
WT (n=5) HE (n=6) WT (n=5) HE (n=6) WT (n=4) HE (n=4) WT (n=4) HE (n=4)
Plasma
Glucose
(mmol/l) - - - - 5.0 ± 0.4 4.5± 0.1 4.5± 2.2 4.4± 0.2
TG
(mmol/l) 0.88 ± 0.3 0.87 ± 0.6 1.13 ± 0.3 0.89 ± 0.5 0.47 ± 0.2 0.62 ± 0.1 0.71 ± 0.2* 0.75 ± 0.1
Tot chol
(mmol/l) 2.99 ± 0.6 2.94 ± 0.6 5.64 ± 0.9a 6.41 ± 0.9b 2.08 ± 0.1 2.17 ± 0.2 4.13± 0.4a* 3.14±0.2b*
FFA
(mmol/l) 1.14 ± 0.3 1.25 ± 0.5 1.13 ± 0.2 1.05 ± 0.1 0.96 ± 0.2 0.90 ± 0.1 0.98 ± 0.1 1.12 ± 0.1
BHB
(mmol/l) 0.55 ± 0.2 0.54 ± 0.0 0.40 ± 0.1 0.28 ± 0.1 2.94 ± 0.3* 2.10 ± 0.5* 1.29 ± 0.1a* 2.78±0.4c*
Liver
Protein
(mg/g) 270.4 ± 59.3 202.7±62.8 151.5±38.2a 135.1±27.9b 108.4 ± 1.4* 95.9 ± 23.2* 76.9± 11.7* 98.0±19.4*
TG
(µmol/g) 15.2 ± 4.6 16.4 ± 12.0 34.2 ± 15.7 46.6 ± 22.1 49.3 ± 7.5* 60.5 ± 18.0* 46.3 ± 9.0 65.5 ± 9.0
Tot chol
(µmol/g) 4.1 ± 1.2 3.7 ± 3.0 6.2 ± 3.7 7.3 ± 3.6b 5.8 ± 0.4 6.6 ± 2.2 5.7 ± 0.7 9.8 ± 1.2c
Free Chol
(µmol/g) 4.7 ± 1.0 4.1 ± 2.0 5.1 ± 2.3 6.4 ± 3.0 - - - -
Glycogeen
(µmol/g) 130.9 ± 54.5 153.7±55.7 203.6 ± 68.7 261.3 ± 42.9 - - - -
MalCoA
(nmol/g) - - - - 22.0 ± 5.3 19.9 ± 3.0 10.2 ± 2.7 10.3 ± 2.6
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tended to be lower both in the fed and fasted state. Th is resulted in an increased 
ratio C(0)/(C16:0+C18:0). Feeding HE mice with the HF diet resulted in a marked 
decrease of C(0)/(C16:0+C18:0), however, this could be fully explained by lower free 
carnitine levels. Moreover, HF feeding abolished the shift  in acylation of carnitine. 
In contrast, in HE mice HF feeding resulted in an even more pronounced decrease 
in free carnitine concentrations when compared to the eﬀ ect in WT mice both in the 
fed and fasted state.
Altered glucose kinetics in CPT1a+/- mice affects plasma glucose and insulin con-
centrations
HF feeding resulted in an increased plasma glucose concentration in both WT and 
HE mice, but insulin levels were not aﬀ ected (Table 3). Aft er the dietary period of 
4 weeks, a bolus of [6,6-2H2]-glucose was injected intraperitonally in both groups 
of mice. Th e decay of the labeled-glucose concentration in time could be fi tted to a 
single compartmental model to calculate (hepatic) glucose production (Ra) and (pe-
ripheral) glucose consumption, expressed as metabolic clearance rate (MCR). Quite 
strikingly, CPT1a heterozygosity induced a two-fold increase both in Ra and MCR 
in mice fed a chow diet. HF feeding induced opposite alterations in WT and HE 
mice; whereas in WT mice HF feeding caused an increased Ra, in HF-fed HE mice 
the MCR was decreased. Th is might indicate that in WT mice the high plasma glu-
cose concentration was due to an increased glucose production whereas in HF-fed 
HE mice a decreased peripheral glucose consumption caused the increased plasma 
glucose concentration.
Table 2: Acyl-carnitine parameters of WT and HE mice fed a chow or high fat diet. Values represent mean ± 
stdev. a: p<0.05 versus WT chow, b: p<0.05 versus HE chow, c: p<0.05 versus WT HF
Acylcarnitines
Chow HF
WT (n=4) HE (n=4) WT (n=4) HE (n=4)
Fed
Total carnitine (μmol/l) 44.8 ± 6.6 48.2 ± 9.0 31.4 ± 3.0a 24.7 ±1.1bc
Free carnitine (μmol/l) 27.7 ± 3.2 31.9 ± 5.3 22.4 ± 1.2 16.2 ± 1.0bc
C0/(C16:0+C18:0) 29.7 ± 3.4 36.4 ± 2.4 36.6 ± 3.6 18.1 ± 3.0bc
Fasted (15 h)
Total carnitine (μmol/l) 41.8 ± 5.2 40.3 ± 1.4 22.2 ± 3.6a 16.5 ± 1.4bc
Free carnitine (μmol/l) 14.5 ± 3.0 16.1 ± 0.6 13.7 ± 2.2 7.5 ± 0.8bc




CPT1a+/- mice display subtle effects on gene expression patterns of enzymes in-
volved in hepatic lipid metabolism
Figure 3 shows hepatic gene expressions levels of enzymes involved in β-oxidation, 
ketogenesis and lipogenesis in 4 h fasted mice. High fat feeding of WT and HE mice 
did not result in signifi cant changes of gene expression patterns. Gene expression of 
both CPT1 genes (Cpt1a and Cpt1b) was not reduced in HE mice, whereas a reduc-
tion of about 50% was expected for the CPT1a gene [7]. Only subtle changes were 
seen. Independent of HF feeding, CPT1a heterozygosity resulted in slight decreases 
in expression of Cpt2, Acc1, Acc2, Ucp1, Scd1 and Hmgs. Th e data obtained aft er 15 
h of fasting were very similar to the data shown in fi gure 2 (data not shown).
Gene expression patterns in skeletal muscle did not show any diﬀ erences between 
genotype and dietary intervention (data not shown).
Table 3: Summary of kinetic parameters a er an i.p. injection of a bolus of [6,6-2H2]-glucose in WT and HE 
mice fed a chow or high fat diet for 4 weeks. Values represent mean ± stdev. a: p<0.05 versus WT chow (start), 














Glucose (μmol/l) 4.2 ± 1.2 4.2 ± 0.7 6.4 ± 1.6 4.2 ± 1.3 4.5 ± 0.4 7.1 ± 3.2
Insulin (μg/l) 0.11±0.03 0.07 ± 0.02 0.09±0.02 0.10±0.02 0.12 ± 0.01 0.09± 0.02
Ra (μmol/kg.min) 21.1 ± 1.9 21.1 and 23.1(22.1 ± 1.4) 39.5±6.4a 42.8±12.3a
38.5 and 45.0
(41.8 ± 4.6) 15.4±7.7bc
MCR (ml/kg.min) 5.3 ± 1.3 5.8 and 4.95.3 ± 0.6) 6.2 ± 0.8 10.4 ± 1.8a
9.1 and 9.5
(9.3 ± 0.2) 2.1 ± 0.3bc
Figure 3: Hepatic gene expression levels of WT and HE mice. Mice were fed either a chow or HF diet for 
4 weeks. Values were aft er 4 hrs of fasting. Values are represented as mean ± stdev. 
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DiscUssion
Heterozygosity for CPT1a-defi ciency in mice has been reported to impair FAO with 
increased fatty acid concentration in plasma aft er 24 h of fasting concomitantly 
with a decrease in plasma glucose concentration [7]. Adenoviral transduction of 
CPT1a in livers of mice protects against high fat feeding-induced insulin resistance 
[8–10]. Th is raised the question whether HF feeding of HE mice would result in 
an enhanced susceptibility to HF feeding-induced glucose intolerance. Our data, 
however, revealed a more complex phenotype. In HE mice the in vitro measured 
malonyl-CoA sensitive CPT1 activity in liver was very similar to WT mice aft er 15 
h fasting. Moreover, expression of Cpt1a in livers of HE mice was even enhanced. In 
plasma, fasting and HF feeding had their well-established eﬀ ects on plasma lipids 
but these eﬀ ects were independent of the genotype. Livers of 15 h fasted HE mice 
showed an increase in hepatic TG content when compared to 15 h fasted WT mice, 
although this diﬀ erence did not reach statistical signifi cance. Moreover, HF feeding 
did not enhance this eﬀ ect. Eﬀ ects of HF feeding and fasting on carnitine content 
were more pronounced in HE mice than in WT mice. Moreover, whole body glucose 
kinetics were also aﬀ ected by heterozygosity for Cpt1a-defi ciency. HE mice on a 
chow diet showed an increased glucose production and clearance although glucose 
concentrations in plasma not diﬀ erent from those observed in WT mice. HF feed-
ing resulted in glucose intolerance as shown by higher glucose concentrations, but 
due to diﬀ erent mechanisms in WT and HE mice. In WT mice, hyperglycemia was 
probably due to increased glucose production whereas in HE mice it was due to a 
small decrease in glucose production accompanied by a more pronounced decrease 
in glucose clearance by the peripheral tissues.
Breeding of mice in which the Cpt1a gene was inactivated resulted in the birth 
of only WT and HE mice and no Cpt1a-/- defi cient mice were born, similar to the 
observations of Nyman et al. [7]. Irrespective of heterozygosity of Cpt1a, expression 
of the gene measured by qPCR was similar to that in WT mice. In this respect, it 
should be realized that the primers and probe used were positioned across the exon-
intron boundary of exon 9, which is still present in the targeted Cpt1a. When we 
measured the resulting in vitro enzyme activity of CPT1a in liver tissue of chow-fed 
mice, we observed that hepatic CPT1 activity in HE mice was very similar to that 
observed in WT mice. Th is in contrast to observations by Nyman et al., who showed 
that hepatic CPT1a activity in 24 h fasted male HE mice was half of that observed in 
WT chow-fed animals [7]. Th e stimulatory eﬀ ect of HF feeding on CPT I activity in 
HE mice appeared to be post-translationally modifi ed: no eﬀ ect on gene expression 
was observed. As yet, the underlying mechanism remains obscure.
In humans only homozygous patients with a CPT1a defi ciency were found to 
display a phenotype, like cardiomyopathy and Reye’s-like syndrome [5,6,23]. Chil-
dren suﬀ ering from a CPT1a defi ciency are more sensitive to metabolic stress like 




the experiments were performed in mice that were too old to show a clear pheno-
type. For this reason, tests in 3-days as well as 14-days old pups were also performed 
(data not shown). In these experiments, however, we did not observe any diﬀ erence 
between the WT and HE pups. Th erefore, it suggests that environmental infl uences 
(housing, food composition) might be more prominent than expected. It should be 
realizes as well that the breeding in our facility was done by intercrossing which 
could have resulted in slight drift  of the genetic make-up of the HE mice compared 
to those used by Nyman et al [7].HF feeding of WT and HE mice did not result in 
diﬀ erent outcome with respect to lipid concentrations in plasma either aft er 4 h or 
15 h of fasting. Moreover, in HE mice fasted for 15 h, glucose intolerance was not 
deteriorated in comparison with WT mice. Th is observation refutes the hypothesis 
that heterozygosity of CPT1a-defi ciency results in enhanced susceptibility of these 
mice to HF feeding-induced insulin resistance.
In liver, the picture was more complex. Fasting chow-fed HE mice resulted in a 
higher TG content of liver in HE mice compared to WT mice. Apparently, partial 
CPT1a defi ciency did result in an unbalanced hepatic lipid metabolism, although 
the in vitro measured enzyme activity was not aﬀ ected. HF feeding did not enhance 
triglyceride storage in liver. Furthermore, changes in hepatic concentration of carni-
tine metabolites on HF feeding were more pronounced in HE mice compared to WT 
mice. Th is also points to changes in hepatic handling of intermediates of fatty acid 
oxidation by impaired expression of Cpt1a, irrespective the normal in vitro activ-
ity of CPT I. Finally, the small changes in expression of genes of enzymes involved 
in malonyl-CoA metabolism also indicate subtle eﬀ ects of Cpt1a heterozygosity on 
liver lipid metabolism.
Th e most obvious eﬀ ect of heterozygosity of Cpt1a-defi ciency was on glucose ki-
netics. In HE mice on chow, hepatic glucose production was twice that calculated for 
WT mice. Furthermore, peripheral glucose consumption was doubled in HE mice 
compared to WT mice. HF feeding has opposite eﬀ ects depending on genotype. In 
WT mice the increased blood glucose concentration brought about by HF feeding 
was due to increased glucose production, while insulin concentrations remained 
unaﬀ ected. It is noteworthy that the hepatic glucose production in HF-fed WT mice 
was not diﬀ erent from that observed in HE mice on chow. It is tempting to speculate 
that livers of HE mice are insulin resistant even on chow. However, the eﬀ ects of 
HF feeding of HE mice on whole body glucose kinetics then become puzzling. In 
HE mice on HF, glucose kinetics slowed down quite drastically. Glucose production 
and glucose consumption decreased 3-fold and 4.5-fold, respectively. Until now, no 
explanation can be given for these observations.
In summary, the results of this study show that heterozygosity for Cpt1a has subtle 
eﬀ ects on hepatic fat and glucose metabolism when mice were fed a chow-based diet. 
We did not observe the same phenotype as was published by Nyman et al [7]. We 
observed normal in vitro enzyme activity in chow fed WT and HE mice. Th e lack of 
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eﬀ ect of HF feeding in HE mice compared to WT mice refuted our hypothesis that 
impairment of hepatic CPT1a activity makes mice more susceptible to diet-induced 
glucose intolerance. In view of the specifi c hepatic eﬀ ects, particularly on glucose 
production, this model shows that the absence of a clear overall phenotype does not 
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